0000899243-23-008752.txt : 20230316
0000899243-23-008752.hdr.sgml : 20230316
20230316175237
ACCESSION NUMBER: 0000899243-23-008752
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230314
FILED AS OF DATE: 20230316
DATE AS OF CHANGE: 20230316
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KIRSKE DAVID
CENTRAL INDEX KEY: 0001276750
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-28386
FILM NUMBER: 23740034
MAIL ADDRESS:
STREET 1: C/O CTI BIOPHARMA CORP.
STREET 2: 3101 WESTERN AVE., SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CTI BIOPHARMA CORP
CENTRAL INDEX KEY: 0000891293
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 911533912
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 800
CITY: SEATTLE
STATE: WA
ZIP: 98121
BUSINESS PHONE: 2062827100
MAIL ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 800
CITY: SEATTLE
STATE: WA
ZIP: 98121
FORMER COMPANY:
FORMER CONFORMED NAME: CELL THERAPEUTICS INC
DATE OF NAME CHANGE: 19960321
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-03-14
0
0000891293
CTI BIOPHARMA CORP
CTIC
0001276750
KIRSKE DAVID
3101 WESTERN AVENUE, SUITE 800
SEATTLE
WA
98121
0
1
0
0
EVP, Chief Financial Officer
Stock Option (right to buy)
4.55
2023-03-14
4
A
0
200000
0.00
A
2033-03-14
Common Stock
200000
200000
D
The stock option will vest in six equal semi-annual installments over a three-year period, subject to continued employment with the Company through the applicable vesting dates.
/s/ David Kirske
2023-03-16